Abstract

BackgroundHere, we cover the development timeline leading up to multiple Phase I clinical trials with an oncolytic adenovirus coding the cytokines TNF-alpha and Interleukin-2 (IL-2). The construction of Ad5/3-E2F-D24-hTNFa-IRES-hIL2 (TILT-123)...

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
Oncolytic adenovirus decreases the proportion of TIM-3+ subset of tumor-infiltrating CD8+ T cells with correlation to improved survival in patients with cancer
Timo Joensuu ... Otto Hemminki
Journal for ImmunoTherapy of Cancer | VOL. 10
Timo Joensuu, et. al.Timo Joensuu ... Otto Hemminki
01 Feb 2022
Abstract B51: Treatment of melanoma with a serotype 5/3 chimeric oncolytic adenovirus coding for GM-CSF: Results in vitro, in rodents and in humans
Timo Joensuu ... Ilkka Liikanen
Cancer Immunology Research | VOL. 3
Timo Joensuu, et. al.Timo Joensuu ... Ilkka Liikanen
01 Oct 2015
Advancing together and moving forward: Combination gene and cellular immunotherapies
Saul J. Priceman ... Waseem Cheema
Molecular Therapy - Oncolytics | VOL. 25
Saul J. Priceman, et. al.Saul J. Priceman ... Waseem Cheema
30 May 2022
Abstract 6656: Revolutionizing solid tumor treatment: Viral protein-targeted CAR-T with oncolytic virus
Soyoung Choi ... Seong-Won Song
Cancer Research | VOL. 84
Soyoung Choi, et. al.Soyoung Choi ... Seong-Won Song
22 Mar 2024
View more papers

More From: Journal for ImmunoTherapy of Cancer

Paper Title
Journal
Date
Author
Development and interpretation of a pathomics-driven ensemble model for predicting the response to immunotherapy in gastric cancer
Zhen Han ... Yuming Jiang
Journal for ImmunoTherapy of Cancer | VOL. 12
Zhen Han, et. al.Zhen Han ... Yuming Jiang
15 May 2024
Colorectal cancer-specific IFNβ delivery overcomes dysfunctional dsRNA-mediated type I interferon signaling to increase the abscopal effect of radiotherapy
Kevin Chih-Yang Huang ... K S Clifford Chao
Journal for ImmunoTherapy of Cancer | VOL. 12
Kevin Chih-Yang Huang, et. al.Kevin Chih-Yang Huang ... K S Clifford Chao
15 May 2024
Correction: Targeting SNORA38B attenuates tumorigenesis and sensitizes immune checkpoint blockade in non-small cell lung cancer by remodeling the tumor microenvironment via regulation of GAB2/AKT/mTOR signaling pathway
-
Journal for ImmunoTherapy of Cancer | VOL. 12
--
13 May 2024
Preliminary efficacy and safety of YSCH-01 in patients with advanced solid tumors: an investigator-initiated trial
Yandong He ... Feng Liu
Journal for ImmunoTherapy of Cancer | VOL. 12
Yandong He, et. al.Yandong He ... Feng Liu
07 May 2024
View more papers